Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse for Negative Symptoms of Schizophrenia
NCT01234298Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- Jan 2012
- Primary completion
- Feb 2014
01
Overview
A Phase 3 trial of lisdexamfetamine in schizophrenia, sponsored by Takeda. Planned start Jan 2012; status: withdrawn.
02
Drugs
lisdexamfetamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01234298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234298.